NASDAQ
$19.52
$19.52

Overview

Price performance
Low
$18.45
High
$22.71
Market closed. Last updated: Nov 4, 2026, 9:00 PM UTC
$
19.52
-0.79 (-3.89%)
Average, 50 days
$22.11
$22.47
Open
$20.85
Previous close
$20.31
52-week high
$30.06
Aug 19, 2026 (3 months ago)
52-week low
$14.64
Nov 7, 2025 (13 months ago)
33.33%

Valuation & Estimates

Earnings

Financials

Insider Trading

Peer Analysis

Insights & Activity

Market Cap
2.30B
Volume
3 321 760
Total Return (3M)
-22.11%
Total Return (1Y)
26.67%
26.74
Sector
Healthcare
Links
Tags
Healthcare
Biotechnology
NASDAQ
US
About
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.